In our previous works, seven of the most potent thiadiazoline-based Eg5 inhibitors, analogs of K858, have been already tested in an in vitro model of stomach tumor, identifying two of them, namely 2 and 41, with a better profile in terms of cancer cells proliferation control, reduction of cell invasiveness and promotion of the apoptotic event [24,25]. This evidence concerns the gene KIF11 and cancer.